• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Azenta Inc.

    9/14/23 5:25:31 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email
    SC 13D 1 tm2326163d1_sc13d.htm SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(a)

     

    Under the Securities Exchange Act of 1934

     

    Azenta, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

    114340102

    (CUSIP Number)

     

    Quentin Koffey

    Politan Capital Management LP

    106 West 56th Street, 10th Floor

    New York, New York 10019

    646-690-2830

     

    With a copy to:

     

    Richard M. Brand

    Cadwalader, Wickersham & Taft LLP

    200 Liberty Street

    New York, NY 10281

    212-504-6000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    September 8, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 574795100   Page 2

     

    1

    NAME OF REPORTING PERSON

    Politan Capital Management LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,133,807

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,133,807

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,133,807

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    6.87%*

    14

    TYPE OF REPORTING PERSON

     

    IA

                     

    * All percentage calculations set forth herein are based upon the aggregate of 60,153,892 shares of Common Stock outstanding as of August 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 9, 2023. 

     

     

     

     

    CUSIP No. 574795100   Page 3

     

    1

    NAME OF REPORTING PERSON

    Politan Capital Management GP LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,133,807

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,133,807

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,133,807

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    6.87%*

    14

    TYPE OF REPORTING PERSON

     

    IA

                     

    * All percentage calculations set forth herein are based upon the aggregate of 60,153,892 shares of Common Stock outstanding as of August 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2023.

     

     

     

     

    CUSIP No. 574795100   Page 4

     

    1

    NAME OF REPORTING PERSON

    Politan Capital Partners GP LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,133,807

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,133,807

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,133,807

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    6.87%*

    14

    TYPE OF REPORTING PERSON

     

    IA

                     

    * All percentage calculations set forth herein are based upon the aggregate of 60,153,892 shares of Common Stock outstanding as of August 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2023.

     

     

     

     

    CUSIP No. 574795100   Page 5

     

    1

    NAME OF REPORTING PERSON

    Quentin Koffey

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,133,807

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,133,807

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,133,807

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    6.87%*

    14

    TYPE OF REPORTING PERSON

     

    IN

                          

    * All percentage calculations set forth herein are based upon the aggregate of 60,153,892 shares of Common Stock outstanding as of August 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2023.

     

     

     

     

    CUSIP No. 114340102   Page 6

     

    ITEM 1.     SECURITY AND ISSUER

     

    This statement on Schedule 13D (“Schedule 13D”) relates to the common stock, par value $0.01 per share (the “Common Stock”), of Azenta, Inc., a Delaware corporation (the “Issuer”). The principal executive offices of the Issuer are located at 200 Summit Drive, 6th Floor, Burlington, Massachusetts 01803.

     

    The Reporting Persons (as defined below) each beneficially owns an aggregate of 4,133,807 shares of Common Stock, including 343,219 shares of Common Stock underlying Physically Settled Swaps (as defined below) described in Item 6. These shares represent approximately 6.87% of the outstanding shares of Common Stock. The Reporting Persons also have additional economic exposure to 385,196 notional shares of Common Stock as further described under Item 6 below, bringing the total aggregate economic exposure of the Reporting Persons to 4,519,003 shares of Common Stock, representing approximately 7.51% of the outstanding shares of Common Stock.

     

    ITEM 2.      IDENTITY AND BACKGROUND

     

    (a), (f) This statement is being filed by:

     

    (i)      Politan Capital Management LP, a Delaware limited partnership (“Politan”);

     

    (ii)     Politan Capital Management GP LLC, a Delaware limited liability company (“Politan Management”);

     

    (iii)    Politan Capital Partners GP LLC, a Delaware limited liability company (“Politan GP”); and

     

    (iv)   Quentin Koffey, a citizen of the United States of America (together with Politan, Politan Management and Politan GP, the “Reporting Persons”).

     

    The Reporting Persons have entered into a joint filing agreement, dated as of August 16, 2022, a copy of which is attached hereto as Exhibit 99.1.

     

    (b) The address of the principal business and principal office of each of the Reporting Persons is 106 West 56th Street, 10th Floor, New York, New York 10019.

     

    (c) Politan’s principal business is to serve as investment advisor to certain funds, including Politan Capital Partners LP, a Delaware limited partnership (“Politan LP”), Politan Capital Offshore Partners LP, a Cayman Islands exempted limited partnership (“Politan Offshore”), and Politan Capital Partners Master Fund LP, a Cayman Islands exempted limited partnership (“Politan Master Fund”) (collectively with Politan Offshore and Politan LP, the “Politan Funds”).

     

    Politan Management’s principal business is to serve as the general partner of Politan.

     

    Politan GP’s principal business is to serve as the general partner of certain affiliated funds, including the Politan Funds.

     

    Mr. Koffey’s principal occupation is to serve as the managing partner and chief investment officer of Politan, and as the managing member of Politan Management and Politan GP.

     

    (d), (e) During the last five years, none of the Reporting Persons (i) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.

     

    ITEM 3.      SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

     

    The responses to Item 4, 5 and 6 of this Schedule 13D are incorporated herein by reference.

     

    The net investment costs (including commissions, if any) of the Common Stock, the Cash Settled Swaps (as defined below) and the Physically Settled Swaps (as defined below) referenced in Items 5 and 6 directly owned by Politan Master Fund is approximately $202,582,505. The source of funding for such transactions was derived from the capital of the Politan Funds.

     

    ITEM 4.      PURPOSE OF TRANSACTION

     

    The Reporting Persons acquired beneficial ownership of the shares of Common Stock described herein in the belief that the Common Stock was undervalued and an attractive investment opportunity.

     

     

     

     

    CUSIP No. 114340102   Page 7

     

    The Reporting Persons have engaged and intend to continue to engage in discussions with certain members of the Issuer’s board of directors and management team regarding the Issuer’s business, operations, financial condition, strategic plans, governance, as well as other matters related to the Issuer, and intend to and may also engage with stockholders, industry analysts and other interested parties with respect to the foregoing.

     

    The Reporting Persons may take or engage in various plans, actions or transactions in seeking to bring about changes to increase stockholder value, and may discuss such plans, actions or transactions with the Issuer and the board of directors and management team of the Issuer, stockholders, industry analysts and other interested parties. The Reporting Persons may change their intentions with respect to any and all matters referred to in Item 4 of Schedule 13D, and may also take steps to explore and prepare for various plans and actions, and propose transactions, before forming an intention to engage in such plans or actions or proceed with such plans, actions or transactions.

     

    The Reporting Persons intend to review their investments in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the outcome of any discussions referenced above, the Issuer’s financial position and strategic direction, actions taken by the Issuer’s management and board of directors, price levels of the Common Stock, other investment opportunities available to the Reporting Persons, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may from time to time and at any time in the future take or engage in various plans, actions or transactions with respect to the investment in the Issuer as they deem appropriate, including, without limitation, purchasing additional shares of Common Stock, disposing of shares of Common Stock, acquiring other financial instruments that are based upon or relate to the value of the Common Stock, selling or obtaining financing on some or all of their beneficial or economic holdings, and engaging in hedging or similar transactions with respect to securities that are based upon or relate to the value of the Common Stock.

     

    ITEM 5.      INTEREST IN SECURITIES OF THE ISSUER

     

    (a), (b) Each of the Reporting Persons beneficially owns an aggregate of 4,133,807 shares of Common Stock (the “Subject Shares”), including 343,219 shares of Common Stock underlying Physically Settled Swaps (as defined below) that the Reporting Persons may be deemed to beneficially own upon satisfaction of certain conditions. The Subject Shares represent approximately 6.87% of the outstanding shares of Common Stock, based on 60,153,892 shares of Common Stock outstanding as of August 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2023. Politan Master Fund also has additional economic exposure to 385,196 notional shares of Common Stock under certain cash-settled total return swaps (“Cash Settled Swaps”), bringing the total aggregate economic exposure of the Reporting Persons to 4,519,003 shares of Common Stock, representing approximately 7.51% of the outstanding shares of Common Stock.

     

    Politan, as the investment advisor to the Politan Funds, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Shares. Politan Management, as the general partner of Politan, which is in turn the advisor to the Politan Funds, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Shares. Politan GP, as the general partner of the Politan Funds, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Shares. Mr. Koffey, as the managing partner and chief investment officer of Politan, and as the managing member of Politan Management and Politan GP, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Shares.

     

    (c) Exhibit 99.2 filed herewith, which is incorporated herein by reference, describes the transactions in the Common Stock that were effected by the Reporting Persons for the benefit of the Politan Funds during the past sixty days.

     

    (d) Politan Master Fund has the right to receive dividends from, and the proceeds from the sale of, the shares of the Subject Shares. No other person is known to the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Subject Shares.

     

    (e) Not applicable.

     

    ITEM 6.      CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

     

    Politan Master Fund has entered into physically settled swaps (the “Physically Settled Swaps”) referencing 343,219 shares of Common Stock in the aggregate that the Reporting Persons may be deemed to beneficially own. Under the terms of each Physically Settled Swap, upon settlement, (i) Politan Master Fund will be obligated to pay to the counterparty the specified price for the specified notional number of shares, plus interest at the rate set forth in the applicable contract and (ii) the counterparty will be obligated to deliver to Politan Master Fund the specified notional number of shares and to pay to Politan Master Fund an amount equal to dividends paid on the specified notional number of shares. The counterparties to the Physically Settled Swaps are unaffiliated third party financial institutions.

     

     

     

     

    CUSIP No. 114340102   Page 8

     

    In addition, Politan Master Fund is a party to Cash Settled Swaps referencing an aggregate of 385,196 shares of Common Stock. Under the terms of each Cash Settled Swap, upon settlement, (a) Politan Master Fund will be obligated to pay to the counterparty any negative price performance of the specified notional number of shares of Common Stock subject to the Cash Settled Swaps, plus interest rates set forth in the applicable contracts, and (b) the counterparty will be obligated to pay to Politan Master Fund any positive price performance of the specified notional number of shares of Common Stock subject to the Cash Settled Swaps. Any dividends received by the counterparty on such notional shares of Common Stock during the term of the Cash Settled Swaps will be paid to Politan Master Fund. All balances will be settled in cash. The counterparty to the Cash Settled Swaps are unaffiliated third party financial institutions.

     

    The Cash Settled Swaps do not give the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer, nor do such agreements require the counterparty thereto to acquire, hold, vote or dispose of any securities of the Issuer. Accordingly, the Reporting Persons disclaim any beneficial ownership of any shares of Common Stock that may be referenced in such contracts or shares of Common Stock or other securities or financial instruments that may be held from time to time by any counterparty to such contracts.

     

    The Politan Funds may, from time to time, enter into and dispose of swaps, options or other derivative transactions with one or more counterparties that are based upon the value of shares of the Common Stock, which transactions may be significant in amount. The profit, loss and/or return on such contracts may be wholly or partially dependent on the market value of the shares of the Common Stock.

     

    On September 14, 2023, the Reporting Persons entered into a Joint Filing Agreement in which the Reporting Persons agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law. The Joint Filing Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Except as described herein, the Reporting Persons have no contracts, arrangements, understandings or relationships (legal or otherwise) with respect to any securities of the Issuer.

     

    ITEM 7.      MATERIAL TO BE FILED AS AN EXHIBIT

     

    Exhibit 99.1 Joint Filing Agreement among Politan Capital Management LP, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, and Quentin Koffey
       
    Exhibit 99.2 Trading Data

     

     

     

     

    CUSIP No. 114340102   Page 9

     

    SIGNATURES

     

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: September 14, 2023

     

      POLITAN CAPITAL MANAGEMENT LP
         
      By: Politan Capital Management GP LLC,
    its general partner
         
      By: /s/ Quentin Koffey
        Name:    Quentin Koffey
        Title: Managing Member
           
      POLITAN CAPITAL MANAGEMENT GP LLC
         
      By: /s/ Quentin Koffey
        Name: Quentin Koffey
        Title: Managing Member
         
      POLITAN CAPITAL PARTNERS GP LLC
         
      By: /s/ Quentin Koffey
        Name: Quentin Koffey
        Title: Managing Member
         
      QUENTIN KOFFEY
         
      By: /s/ Quentin Koffey
        Name: Quentin Koffey

     

     

     

     

    CUSIP No. 114340102   Page 10

     

    INDEX TO EXHIBITS

     

    Exhibit   Description
         
    Exhibit 99.1   Joint Filing Agreement among Politan Capital Management LP, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, and Quentin Koffey
         
    Exhibit 99.2   Trading Data

     

     

     

    Get the next $AZTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZTA

    DatePrice TargetRatingAnalyst
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    4/4/2024$64.00Hold
    Jefferies
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    7/19/2023Mkt Perform
    Raymond James
    5/10/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    2/9/2023$65.00 → $60.00Overweight → Equal-Weight
    Stephens
    1/3/2023$60.00 → $62.00Outperform → In-line
    Evercore ISI
    3/31/2022$106.00Buy
    B. Riley Securities
    More analyst ratings

    $AZTA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Azenta Inc.

      10-Q - Azenta, Inc. (0000933974) (Filer)

      5/9/25 4:07:49 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Azenta, Inc. (0000933974) (Filer)

      5/7/25 7:05:31 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Azenta, Inc. (0000933974) (Filer)

      4/9/25 4:30:57 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Azenta upgraded by Stephens with a new price target

      Stephens upgraded Azenta from Equal-Weight to Overweight and set a new price target of $60.00 from $50.00 previously

      12/18/24 7:25:24 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Jefferies initiated coverage on Azenta with a new price target

      Jefferies initiated coverage of Azenta with a rating of Hold and set a new price target of $64.00

      4/4/24 7:29:19 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • B. Riley Securities reiterated coverage on Azenta with a new price target

      B. Riley Securities reiterated coverage of Azenta with a rating of Buy and set a new price target of $79.00 from $61.00 previously

      2/1/24 8:17:35 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

      NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin

      11/19/24 5:56:00 PM ET
      $AZTA
      $CON
      $ENV
      $FLEX
      Industrial Machinery/Components
      Technology
      Medical Specialities
      Health Care
    • Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

      William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i

      11/4/24 8:00:00 AM ET
      $AZTA
      $BV
      $LVWR
      Industrial Machinery/Components
      Technology
      Business Services
      Consumer Discretionary
    • AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

      Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition.  Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P

      9/4/24 8:00:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

      BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

      5/7/25 6:30:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast

      BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

      4/24/25 4:15:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Publishes its 2024 Environmental, Social, & Governance (ESG) Report

      BURLINGTON, Mass., March 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2024. The report offers a comprehensive look at the Company's ESG approach and showcases accomplishments in three main pillars: Environmental Protection: We understand the broad impact of our operations and the potential to impact the world. We are committed to evaluating ways to reduce our environmental footprint while continu

      3/24/25 4:05:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Financials

    Live finance-specific insights

    See more
    • Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

      BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

      5/7/25 6:30:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast

      BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

      4/24/25 4:15:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024

      BURLINGTON, Mass., Feb. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the fourth fiscal quarter of 2024 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 148 $ 151 $ 142 (2) % 4 % Organic growth 4 % Sample Management Solutions $ 81 $ 85 $ 79 (4) % 3 % Multiomics $ 66 $ 66 $ 63 0 % 6 % Diluted EPS Continui

      2/5/25 7:00:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Azenta Inc.

      SC 13G/A - Azenta, Inc. (0000933974) (Subject)

      11/13/24 4:05:02 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Amendment: SEC Form SC 13D/A filed by Azenta Inc.

      SC 13D/A - Azenta, Inc. (0000933974) (Subject)

      11/4/24 8:41:47 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • SEC Form SC 13G filed by Azenta Inc.

      SC 13G - Azenta, Inc. (0000933974) (Subject)

      10/31/24 11:55:02 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AZTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and General Manager, Genom Zhou Ginger bought $19,132 worth of Common (417 units at $45.88), increasing direct ownership by 2% to 27,916 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/4/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • President and CEO Marotta John was granted 83,622 units of Common and bought $552,904 worth of Common (13,967 units at $39.59), increasing direct ownership by 2,982% to 100,862 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:16 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Cornog William L bought $495,000 worth of Common (12,500 units at $39.60) (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:11 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • EVP, CFO and Treasurer Lin Lawrence Y. was granted 2,200 units of Common, increasing direct ownership by 6% to 37,513 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/13/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Koffey Quentin was granted 4,040 shares, increasing direct ownership by 406% to 5,035 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/11/25 4:48:51 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Malus Alan J was granted 4,040 units of Common, increasing direct ownership by 406% to 5,035 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/11/25 4:10:12 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology